GN-CORPORATION
8.8.2024 08:59:37 CEST | Business Wire | Press release
Nichi BRITE Beta glucan administration resulted in enhancement of immunity followed by reduction in biomarkers of pancreatic cancer and that of its recurrence in patients undergoing surgical resection of malignant pancreatic tumor, which was presented at the ASCO® Breakthrough meeting in Yokohama, Japan. IgA and CD209, markers of immunity enhanced while CA19-9, the marker of pancreatic cancer and CD44, that of cancer recurrence and severity, significantly reduced in patients who had Nichi BRITE, compared to the control group in the study by gastro-enterology surgeons and nutritional support team of Chikamori Hospital, Kochi, Japan. Importantly, the mean survival improved after Nichi BRITE administration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807498226/en/
The Nichi BRITE Beta 1,3-1,6 Glucan is produced as an exo-polysaccharide by Aureobasidium Pullulans in a GMP certified facility in Japan and is water soluble. The subjects of Nichi BRITE group in the study were given 250mg Beta glucan as an active ingredient per day for 22 days as an adjuvant, while control group had a placebo instead; both groups were given standard of care treatment. The quantity consumed during the study by each patient is equivalent to four boxes of Nichi BRITE, which comes in a box of 24 sachets, 1.5-gram granule as content with 63 mg active beta glucan as ingredient per sachet. Oral administration was undertaken when possible, and when it was not possible, administration was through feeding gastrostomy or nasogastric tube. No adverse reactions were observed. The efficacy in terms of immune enhancement, cancer biomarker reduction and longer mean survival were reported with Nichi Brite as an adjuvant. (Graphic: Business Wire)
Pancreatic cancer has a very poor prognosis. Earlier data of Nichi BRITE allergen-free food supplement on safety and efficacy in improving the immune system, decreasing tumor size in animal models and improving NK cell cytotoxicity in healthy volunteers, elderly people and cancer patients formed the basis of this clinical study. In the study, Nichi BRITE beta glucans were administered from one-day prior to the surgery, until 21st post-operative day, either orally or through feeding gastrostomy. There were no adverse reactions with Nichi BRITE and the outcome was very encouraging, said Dr Akira Tsukada, Chief Hepato-biliary pancreatic surgeon.
The immune enhancement parameters increased in the Nichi BRITE consumed group compared to the control group. IgA level improved, which is the first line of defense against infections, and CD209 improved significantly, which represents monocyte derived dendritic cells that present foreign antigens for destruction by the immune system. Such immune enhancement, the researchers consider, has led to decline in CD44 cancer stem cells that cause metastases, reduction of pancreatic cancer marker CA19-9 and prolongation of lifespan evident by longer mean survival, confirming the multipronged advantages of Nichi BRITE.
While thanking Dr. Masanori Chikamori, Emeritus chairman for his initiatives, and Prof. Nobunao Ikewaki of Kyushu University of Medical Science who undertook the laboratory investigations, they recommend consideration of Nichi BRITE as a routine onco-nutrition supplement to be included in the clinical nutrition guidelines for patients undergoing surgical procedure for cancer and other conditions.
Nichi BRITE is not a drug or remedy to any illness and doesn’t carry any therapeutic claims. Research findings are for the understanding of healthcare professional and not to be construed as medical advice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807498226/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Taktile Secures $110M in Goldman Sachs-led Series C to Power AI Transformation in Financial Institutions24.6.2026 15:30:00 CEST | Press release
Growth Equity at Goldman Sachs Alternatives backs Taktile as a leading enabler of AI-driven efficiency and performance gains in banks and insurers. Taktile, the leader in AI transformation for financial institutions, today announced its $110 million Series C fundraise. Growth Equity at Goldman Sachs Alternatives led the round, with participation from Balderton Capital, Index Ventures, Tiger Global, Y Combinator, and Dig Ventures. Taktile Fast Facts Taktile enables banks and insurers to transform into AI-native organizations that are increasingly powered by autonomous agents. Demand for Taktile accelerated in 2025, as AI models became capable of automating high-stakes decisions that previously required hours of manual work—from underwriting business loans and assessing claims to catching financial crime. Customers automate and optimize decisions with Taktile by combining its financial services expertise and product built for sector-specific AI use cases. One of the world’s largest insur
New MetLife Study Reveals a 72% “Confidence Gap” in Ability to Recover from Life's Setbacks24.6.2026 15:25:00 CEST | Press release
Multinational study finds preparedness, early life experiences, and community support play a critical role in building resilience and confidence, reinforcing MetLife’s purpose. Sports, education, and mentorship at a young age shape long-term confidence and resilience. MetLife and MetLife Foundation are supporting initiatives like the FIFA Global Citizen Education Fund to expand access to education and sports programs for youth in communities worldwide, supporting their future success. A new multinational study from MetLife reveals a striking “confidence gap”: while most adults describe themselves as resilient, their confidence drops by 72% when faced with real-life setbacks. The Confident Pathways Report, conducted across the United States, United Kingdom, Japan, and Mexico, was designed to better understand how confidence is built and sustained throughout life. The findings underscore the role of opportunity, preparedness, and support in building confidence - factors that help people
StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide24.6.2026 15:08:00 CEST | Press release
Simple, user-friendly product enables effective cytology cell concentration without complex steps, integrating seamlessly into existing pathology workflows. StatLab Medical Products, a leading global developer and manufacturer of pathology supplies and equipment, today announced the global launch of the CytoPath Disc, an innovative cell block preparation technology designed to standardize and simplify cell block preparation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624368623/en/ Developed as an alternative to traditional cell block methods, which convert concentrated cells suspended in fluid into a paraffin-embedded format for slide-based evaluation, the patent‑pending CytoPath Disc offers a more streamlined and efficient approach. The CytoPath Disc absorbs concentrated cells within a simple, sponge-like matrix, which is then processed, embedded, stained, and sectioned using standard histology workflows. Traditional
TensorX Launches With €8M Seed Funding Round Led by Darius Cubed Ventures for Bet on European Sovereign AI Infrastructure With Plans to Deploy up to €100M in NVIDIA Blackwell GPUs24.6.2026 15:07:00 CEST | Press release
TensorX launches privacy-first inference, already trusted by financial services firms and AI consultancies across Europe62% of European organisations now seek sovereign AI (Accenture) as 75% plan to move AI workloads to local providers by 2030 (Gartner) A team of Irish founders has committed €8 million to Nvidia Blackwell GPUs, including the latest B300 chips, to launch TensorX, a sovereign AI inference platform designed for Europe's AI builders, trusted by regulated industries and already generating revenue from paying customers. The company was founded by Shane Morton, is part of the NVIDIA Inception program and is partnering with Dell on sourcing GPU hardware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528791384/en/ (From left to right): Craig Donnelly, Shane Morton, Nicole Morton, Tim Grant At a time when enterprises are racing to adopt artificial intelligence but most remain unwilling to let their data leave Euro
Wasabi Launches Wasabi Impact Circle to Help Customers and Partners Reduce Cloud Emissions and Support Carbon Projects24.6.2026 15:00:00 CEST | Press release
Powered by Zero Circle, the new offering enables partners and MSPs to help track customers’ storage-related emissions and invest in high-integrity climate projects Wasabi Technologies, the hot cloud storage company, today announced Wasabi Impact Circle, a new sustainability initiative designed for partners and MSPs to help measure and address the carbon emissions associated with their customers’ cloud storage usage. Powered by Zero Circle, a sustainable finance marketplace, Wasabi Impact Circle enables partners and MSPs to help customers track their storage-related carbon footprint and purchase high-integrity carbon credits from curated, verified climate projects worldwide. Research from Wasabi shows that sustainability is among the top considerations for organizations when selecting a cloud storage provider. As enterprises face increasing pressure to reduce emissions, especially amid rising AI-driven data growth, Wasabi Impact Circle provides a simple, transparent way for partners to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom